Table 1.
Metabolic modulators arising from the metabolic theory of cancer.
| Target | Therapy | Reference |
|---|---|---|
| Glucose transporters (GLUTs) | 2-deoxyglucose (2DG) | (92, 93) |
| Phloretin | (49, 71) | |
| Silybin | (26, 94) | |
| Glutor | (95) | |
| STF-31 | (94, 96) | |
| WZB117 | (94, 96) | |
| Fasentin | (97, 98) | |
| Hexokinase (HK) | 2-deoxyglucose (2DG) | (92, 93) |
| 3- bromopyruvate (3BP) | (26, 96) | |
| Lonidamine(LND) | (99, 100) | |
| Methyl jasmonate | (94, 97) | |
| Glyceraldehyde 3-phosphate dehydrogenase(GAPDH) | 3- bromopyruvate (3BP) | (26, 96) |
| Ornidazole, a-chlorohydrin | (24) | |
| Phosphofructokinase (PFK) | 3-(3-pyridinyl)-1-(4-pyridinyl)- 2-propen-1-one (3PO) | (26, 93) |
| Pyruvate kinase-M2 (PK-M2) | TLN-232/CAP-23 | (26, 92, 94) |
| Shikonin | (24, 26) | |
| Alkannin | (24, 26) | |
| TEPP-46 | (24, 86) | |
| DASA-58 | (24, 101) | |
| ML-265 | (17, 102) | |
| Oleanolic acid (OA) | (103) | |
| dimethylaminomicheliolide(DMAMCL) | (104) | |
| Lactate dehydrogenase (LDH) | 2,3-dihydroxynaphtalen-1-carboxylic acid (FX11) | (24, 94) |
| N-hydroxy-2-carboxy-substituted indoles (NHI) | (24, 105) | |
| Oxamate | (24) | |
| R-(-)-gossypol / AT101 | (24) | |
| 3-hydroxyisoxazole-4-carboxylic acid (HICA) | (26, 34) | |
| Gossypol/Galloflavin | (52) | |
| 5 designed peptides(QLYNL, LIYNLL, IYNLLK,KVVYNVA, and KVVYNV) | (52) | |
| 1-(Phenylseleno)-4-(Trifluoromethyl) | (52) | |
| Benzene(PSTMB) | (24, 105) | |
| Oxamate(siRNA LDHA gene, Galloflavin) | (92, 96) | |
| FK866 | (26, 52) | |
| AZD3965 | (24, 52) | |
| AR-C155858 | (95, 106) | |
| a-cyano-4-hydroxycinnamic acid (CHC), 4,4-diisothiocyanatostilbene-2,2′ -disulphonic acid(DIDS), Quercetin | (52, 106) | |
| BAY-8002 | (52) | |
| Syrosingopine | (52) | |
| Isocitrate dehydrogenase (IDH) | AGI-5198 | (102, 107) |
| AGI-6780 | (102, 108) | |
| PDK | TKIS | (52, 102) |
| Dichloroacetate (DCA) | (14, 49) |